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Abstract
Medical imaging methods are assuming a greater role in the workup of patients with COVID-19, mainly in relation to the primary
manifestation of pulmonary disease and the tissue distribution of the angiotensin-converting-enzyme 2 (ACE 2) receptor.
However, the field is so new that no consensus view has emerged guiding clinical decisions to employ imaging procedures such
as radiography, computer tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, and in what
measure the risk of exposure of staff to possible infection could be justified by the knowledge gained. The insensitivity of current
RT-PCR methods for positive diagnosis is part of the rationale for resorting to imaging procedures. While CT is more sensitive
than genetic testing in hospitalized patients, positive findings of ground glass opacities depend on the disease stage. There is
sparse reporting on PET/CT with [18F]-FDG in COVID-19, but available results are congruent with the earlier literature on viral
pneumonias. There is a high incidence of cerebral findings in COVID-19, and likewise evidence of gastrointestinal involvement.
Artificial intelligence, notably machine learning is emerging as an effective method for diagnostic image analysis, with perfor-
mance in the discriminative diagnosis of diagnosis of COVID-19 pneumonia comparable to that of human practitioners.
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic has
seen an unprecedented response of the scientific community;
a search in the PubMed database at the time of writing this
review yields nearly 100,000 scientific papers that appeared in
the span of less than 1 year. For the sake of comparison, it took
nearly 14 years to accrue that many citations for the search
item HIV following the start of that ongoing pandemic. The
unprecedented research effort sparked by the COVID-19 pan-
demic has yielded substantial findings in the epidemiology,
immunology, comorbidity, basic physiology and therapeutics,
genetics of the COVID-19 virus, and a large literature on
sociological and psychological aspects. A historical compari-
son with the HIV epidemic is imperfect due to the intervening
exponential growth of the entire biomedical literature, which
has been doubling every 10–15 years, with no sign of abating.
This exponential growth of the biomedical literature holds
across a broad range of topics, including infectious diseases
and medical imaging, but the recent growth of the COVID-19
literature seems without historical precedent. Even confining
the search to the present matter of interest, i.e., the use of
medical imaging in the context of COVID-19, yields more
than 5000 articles published in the course of the year. This
flood of information calls for a careful extraction of the most
salient findings, best accomplished by the process of system-
atic or narrative reviews of the literature. Reviews of radiolog-
ical investigations of COVID-19 have naturally emphasized
thoracic imaging [1, 2], as have reviews of findings with [18F]-
FDG/PET [3]. A few studies have taken the broader perspec-
tive of compiling imaging findings by CT, PET, and MRI [4],
while addressing the multi-systemic clinical manifestations of
COVID-19.
Indeed, the protean manifestations of COVID-19 patholo-
gy are evident in studies showing associations with cardiovas-
cular [5], gastrointestinal [6], and neurological imaging results
[7], with a few articles emphasizing the multisystem imaging
findings [8]. Other studies report on the use of imaging for
moni to r ing the ef f icacy of t rea tments , such as
methylprednisone [9] or viral protease inhibitor [10]. In the
present review, we have compiled a broad overview of PET,
CT, and MR imaging results for the diagnosis and treatment
monitoring of COVID-19. Some proportion of the burgeoning
literature presents case studies with atypical presentations or
manifestations of the infection. However, we have attempted
herein to distill the main findings that are informative about
the most commonly encountered symptoms and pathologies,
which naturally places our main emphasis on indices of pres-
ent infection in the respiratory tract. Our objective is to depict
the broader utility of medical imaging for detecting COVID-
19-associated pathologies involving the nervous system and
sensory, musculoskeletal, and cardiovascular systems, as well
as renal, gastroenterological, and dermatological involvement.
Chest imaging
Computed tomography of the lungs and chest
radiography
Indication for imaging
Rapid and accurate diagnosis of COVID-19 is critically im-
portant for treatment decisions and taking appropriate isola-
tion measures. The real-time reverse transcription polymerase
chain reaction (RT-PCR) assay represents the standard of ref-
erence for detection of viral particles. However, reports from
China have suggested a rather imperfect sensitivity of RT-
PCR, ranging between 60 and 97% [11–13]. While RT-PCR
provides near-perfect specificity with no misidentification of
other coronaviruses or respiratory infectious agents, a number
of factors including the quality and handling of specimens can
reduce the test sensitivity in practice. Most importantly, the
viral load of SARS-CoV-2 in different tissues changes dra-
matically across disease stages [14]. Up to four serial false-
negative RT-PCR tests have been reported with delay of def-
inite diagnosis by up to 5.1 ± 1.5 days [15]. Furthermore, ra-
diological findings may not occur in simple temporal associ-
ation with the stage of rapid viral proliferation.
Computed tomography (CT) has unsurpassed sensitivity to
detect even subtle pulmonary changes due to respiratory dis-
ease. Unsurprisingly, CT has a high sensitivity for diagnosis
of COVID-19. Nevertheless, CT results are also dependent on
disease stage and are likely to be negative in asymptomatic
patients or in up to 56% of symptomatic patients within the
first 2 days of symptom onset. The rate of false-negative CT
findings decreased to 9% at 3–5 days of symptomatic disease,
and to only 4% at 6–12 days after first symptoms [16]. Of
note, a recent literature review indicates in particular that pe-
diatric patients with COVID-19 infection often have normal
findings to CT imaging (26.5%) [17]. Thus, a normal thoracic
CT cannot exclude an SARS-CoV-2 infection, especially in
the early phase of disease. However, in symptomatic patients
with high clinical suspicion of COVID-19 and a negative or
undetermined RT-PCR test, CT can be used to diagnose pul-
monary changes that are—depending on their pattern—more
or less suggestive for a SARS-CoV-2 infection. In this man-
ner, imaging might be used to triage patients rapidly before
definitive RT-PCR results are available, which could be logis-
tically very useful, especially when health care facilities are
suffering a high caseload. The implementation of chest CT for
this purpose has been widely discussed. Most recommenda-
tions, such as the ACR statement as well as the position paper
issued by the Fleischner society, however, advocate the use of
chest CT only in particular clinical scenarios and in selected
patient populations [18, 19]. Chest radiography is ordinarily
part of the diagnostic work-up in many patients presenting
with symptoms of pneumonia, irrespective of cause. Even
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after several days of COVID-19 respiratory symptoms, the
chest radiograph can be negative, if parenchymal changes
are too subtle to be captured or difficult to differentiate from
preexisting lung disease. CT is generally superior to radiogra-
phy, but also the diagnostic performance of CT varies with
disease stage: false negative CT reports declined from 37% in
days 0–2 to 28% in days 3–5 and 19% in days 6–9 [20],
somewhat mirroring the disease progression.
A number of professional societies have published recom-
mendations on the role of imaging in the diagnosis of COVID-
19, including the European Society of Radiology together
with the European Society of Thoracic Imaging (ESR/ESTI),
the Fleischner Society, and the British Society of Thoracic
Imaging (BSTI) [21–23]. Recommendations concur that the
indication for CT imaging should be a matter of the severity of
respiratory symptoms of the patients, with consideration of the
local prevalence of the disease and the status of health care
facilities. CT imaging is not indicated in patients with mild
symptoms, but an initial chest radiograph seems appropriate to
diagnose the presence and extent of pulmonary opacifications
in patients with moderate to severe symptoms. CT should be
reserved for high-risk patients or those suspected of having
complications or worsening of respiratory status, and for pa-
tients in need of expedited case management despite a present
lack of definitive RT-PCR results. Typical CT findings for
COVID-19 can be hard to distinguish from those with other
viral infections (e.g., influenza) or non-infectious diseases
(e.g., organizing pneumonia). The accuracy of image interpre-
tation is therefore highly dependent on the local disease prev-
alence at the time of investigation. Combining CT findings
with laboratory findings such as white blood cell count and
lymphocytopenia reportedly increases diagnostic accuracy
[24, 25].
In general, one critical aspect in the management of pa-
tients during the COVID-19 pandemic is to need to ensure
the safety of non-infectious patients and personnel, not only
in radiology departments but also throughout the hospital.
Therefore, specific measures are required in order to minimize
virus dissemination and contamination of imaging equipment.
The American College of Radiology recently emphasized
helpful measures [26].
Pathogenesis of COVID-19 pneumonia
Despite extraordinary efforts in the past year, the pathogenesis
of COVID-19 pneumonia remains poorly understood. SARS-
CoV-2 infects cells expressing the angiotensin-converting-
enzyme 2 (ACE 2) receptor in their plasma membrane [27].
In humans, there is high expression of ACE 2 on ciliated
epithelial cells of the respiratory tract and to a lesser degree
on pneumocytes type II and alveolar macrophages, which ex-
plains the propensity of SARS-CoV-2 to cause pneumonia
(Fig. 1). Autopsy and biopsy studies have demonstrated that
the initial phase of COVID-19 pneumonia manifests in diffuse
alveolar damage (DAD), with the formation of hyaline mem-
branes and the desquamation of pneumocytes, as likewise
observed in acute respiratory distress syndrome (ARDS)
[27]. Features of acute bronchitis and bronchiolitis are also
common. Furthermore, vascular damage is often seen in
COVID-19 patients, presenting either as thromboembolism
of larger blood vessels and/or as intravascular clot formation
in capillaries that resembles neutrophilic capillaritis [27]
(Fig. 2).
Imaging findings on chest radiographs
Chest radiographs, although not as sensitive as CT, are the
diagnostic mainstay in many centers. The most commonly
observed COVID-19 findings on chest radiographs are air
space opacities including consolidation and ground glass
opacities, also reticular abnormalities occur. These patterns
have a bilateral distribution in the mid-lung field or basally
with a peripheral predominance [20, 28, 29].
Imaging findings on chest CT
The most common CT pattern is either isolated ground-glass
opacities, which are observed in one half of COVID-19 pa-
tients, or a combination of ground-glass opacities and consol-
idations, which is observed in around 44% of patients (Fig. 3)
[30]. These typical findings most likely reflect pulmonary
edema with hyaline membrane formation, as was reported in
an autopsy series [27, 31]. Isolated consolidations are ob-
served in 24% of patients [30], with an increasing prevalence
as the disease progresses. In addition to ground glass and
consolidations, other typical findings in COVID-19 are
engorged pulmonary vessels (64%), septal thickening (60%),
and pleural thickening (42%), as well as the so-called crazy
paving pattern represented by ground glass opacities in
Fig. 1 Electron transmission micrograph showing an alveolar type II cell
with its characteristic lamellar bodies (arrowheads) and a group of
coronaviruses (circle)
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combination with underlying interlobular septal thickening,
and the reversed halo sign [30, 32]. The reported distribution
of the pulmonary CT findings is bilateral (79%), multifocal
(70%), or sometimes patchy, with a predominance of the lung
periphery and the bases of the lung [33–37]. In other patients,
the abnormalities show a preferential bronchovascular (12%)
or diffuse distribution (44–59%) [37–39]. Based on chest CT
patterns, a grading into low, moderate or high level of suspi-
cion for COVID-19 pneumonia has been proposed, aiming to
facilitate communication of the findings [40].
Although imaging findings of pulmonary involvement are
relatively characteristic of COVID-19, they are not specific
for this disease. Underlying conditions might influence the
imaging presentation, requiring careful consideration of any
previous patient history [41–43]. Other entities such as influ-
enza virus or respiratory syncytial virus may mimic radiolog-
ical aspects of COVID-19 pneumonia [44]. The pattern of
distribution of finding in the lungs as well as the composition
of parenchymal opacities may assist in the discrimination
between viral etiologies. For instance, influenza pneumonia
is reported to present with dense opacifications, whereas
COVID-19 is characterized by more prevalent ground glass
density [41].
Over the course of the COVID-19 illness, the relative pro-
portion of ground glass opacities decreases, whereas the pro-
portion of consolidations and reticular abnormalities tends to
increase [45, 46]. The extent of consolidations peaks between
day 9 and 13 after the initial onset of symptoms [46, 47].
Importantly, the gradual resolution of abnormalities can take
several weeks [47]. In some patients, however, the diffuse
alveolar damage in COVID-19 may lead to an adult respira-
tory distress syndrome (ARDS) and life-threatening multi-or-
gan dysfunction [48]. CT findings in patients with ARDS
secondary to COVID-19 show extensive bilateral ground
glass opacities with or without admixed consolidations [49].
An increasing number of imaging and autopsy studies also
report lung fibrosis as a long-term consequence of COVID-
19 with traction-bronchiectasis and fibrotic bands [50–52].
Importantly, pleural effusion, cavities, lymphadenopathy, mu-
cous plugging, and tree-in-bud are uncommon findings in
COVID-19, and their presence should thus raise the suspicion
of a bacterial superinfection or other complications [53, 54].
Initial reports also address the issue of late effects in recovered
patients following COVID-19 [55, 56]. Figure 4 shows lung-
imaging sequelae of severe COVID-19.
Imaging findings on lung ultrasound
Lung ultrasound (LUS) findings in COVID-19 pneumonia
depend primarily on the phase of the disease, as well as dis-
ease extent. In earlier stages, in which CT shows primarily
ground-glass opacities, LUS is characterized by an increased
number of the so-called B-lines, which are defined as
hyperechoic lines radiating vertically from the pleura into
the lung parenchyma [57–62]. The pleura frequently appears
Fig. 2 Micrograph of a hematoxylin and eosine-stained lung tissue sam-
ple of a patient with severe COVID-19 pneumonia showing a small sized
artery filled with a fibrin-rich thrombus with signs of organization
Fig. 3 Three different patients with COVID-19 related abnormalities in
the lungs shown by non-contrast CT. a A 55-year-old male patient with
COVID-19 diagnosed 1 day before. CT showing ill-defined ground glass
nodules in both lungs (yellow arrows). bA 49-year-old male patient with
acute dyspnea for 4 days. CT showing extensive ill-defined
consolidations with positive air-bronchograms in both lower lobes:
COVID-19 was confirmed by RT-PCR. c A 60-year-old male patient
with consolidations in the lung periphery sparing the subpleural space.
The findings are compatible with organizing pneumonia indicating ongo-
ing repair of the known COVID-19 pneumonia
Eur J Nucl Med Mol Imaging
rugged [61]. As with CT, these findings are predominantly
evidence in the lower lobes. With increasing severity of
COVID-19 pneumonia, the number of these B-lines increases,
and they may coalesce and involve larger areas of the lung.
Furthermore, hypoechoic lung consolidations with or without
air bronchograms may be observed [62]. Importantly, LUS
findings—as also other imaging modalities—have a certain
sensitivity of COVID-19, but are not specific.
LUS is used as a decision-making and disease-monitoring
tool in COVID-19 patients [62]. As such, LUS serves primar-
ily as a triage tool in the emergency room, to guide decisions
about mechanical ventilation (PEEP titration) in the intensive
care unit and as a monitoring tool to diagnose complications
such as pleural effusions or intrapulmonary abscesses [58].
Prognostication of patient outcome
The aim of many prognostic studies has been to assess pro-
spectively the risk of critical illness calling for mechanical
ventilation and potentially leading to death, where the restrict-
ed availability of ventilators and staff at critical care facilities
has been an important vexation. This kind of risk prediction
remains quite challenging and must accommodate various
factors such as comorbidities and laboratory findings, as well
as treatment, which has been evolving over time in the pan-
demic. Thus, interpretations of the results of prognostic stud-
ies require some caution in light of these considerations.
A meta-analysis including 13 studies and 3027 patients iden-
tified age > 65, current smoking, and various comorbidities such
as hypertension, diabetes, cardiovascular disease, and chronic
lung disease as risk factors for progression to critical and mortal
outcomes [63]. Multiple publications have described various as-
sociations between laboratory findings with poor prognosis or
critical illness. Notably, elevation of CRP, LDH, Ferritin,
Procalcitonin, D-dimer, Il-6, and cardiac enzymes is a character-
istic of more severe cases [64, 65].
In addition to consideration of patient characteristics and
clinical parameters, imaging has also played an important role
in the prediction of patient outcome. Among the findings that
have been proposed as indicators of disease severity are visual
assessment of >25% involved lung parenchyma [66], which
mirrors the threshold of less than 73% well–aerated lung pa-
renchyma on admission chest CT [67]. In addition, several
studies emerging from China have confirmed the relationship
between extent of parenchymal changes on CT and patient
outcome. However, these studies generally failed to consider
the influence of confounding factors.
A number of CT severity scores have been proposed based
on visual assessment of involved lung parenchyma, using ei-
ther small increments (< 10%, 10–25%, 25–50%, 50–75%, >
75%, [21]) or assessing the involvement (0, < 50% or > 50%)
per lung segment [68]. A threshold of 19.5 of 20, correspond-
ing to about 50% of involved lung tissue, yielded a ROC area
under the curve (AUC) of 0.892 for identifying severe
COVID-19 disease. Artificial intelligence methods are now
finding application for quantification of involved lung paren-
chyma, with high agreement scores with observer results [69],
as we shall described in detail below.
As for CT, there are a number of publications using a read-
ing of the admission chest radiograph (CXR) together with
clinical and laboratory finings for risk predication. While
Toussie et al. targeted only patients <50 years and did not
consider laboratory findings [70], Liang et al. developed a risk
score consisting of CXR findings and laboratory findings in a
large Chinese data cohort across a broad age range. In their
patients with generally less severe illness, the risk score had a
very high discriminatory value (AUC 0.88) [71]. Schalekamp
and coauthors developed a risk score for a more challenging
group of patients with moderate to severe symptoms who were
hospitalized [72]. The final risk model (*DUTCH COVID-19
risk model) included gender, COPD, symptom duration, in-
flammatory laboratory parameters (neutrophil count, C-
Fig. 4 Axial CT section at the level of the lower lobes in a patient 4
months after severe COVID-19 pneumonia. Focal, subpleural reticula-
tions with associated volume loss (image a, arrow) and subpleural bands
(arrowheads in a) represent residual fibrous foci. Axial minimal intensity
projections (10-mm slice thickness; image b) picture peripheral traction
bronchiectasis. In addition, a common finding in post-COVID-19 patients
is multifocal air-trapping (asterisk in b) pointing towards involvement of
small airways
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reactive protein, LDH), and CXR findings. Risk-determining
CXR findings were the distribution of opacifications (central/
diffuse versus peripheral only) and their extent (0, < 50%, and
> 50%) separately for the four quadrants of the posteroanterior
radiograph. Another Dutch group has followed a similar ap-
proach of combining CXR and laboratory findings [73].
We note that the risk and occurrence of pulmonary embo-
lism was not included in the risk models mentioned above.
While concentration and increases of D-dimer have emerged
as an important risk factor, we are not aware of any publica-
tions yet showing an association between the extent of paren-
chymal findings and the occurrence of pulmonary embolism.
PET/CT
Since the beginning of the pandemic, a number of case re-
ports, letters to editors, and case series have been published
reporting [18F]-FDG-PET/CT imaging findings in patients
with RT-PCR-confirmed SARS-CoV-2 infection (Fig. 5).
Intriguingly, as with CT, there are several case reports of
PET/CT findings in otherwise asymptomatic individuals,
and indications that CT can reveal sub-clinical infection. In
consideration of known issues regarding the low sensitivity
for RT-PCR [74–76], a number of authors have proposed CT
as a potential screening tool, although official guidance re-
mains firmly against using CT as an initial screening test.
Despite the numerous case reports enthusiastically suggesting
a potential role for [18F]-FDG-PET/CT [77, 78], there is not
yet any clear evidence-based rationale for molecular imaging
in the diagnosis or management of COVID-19.
A large body of historical literature exists on the molecular
imaging of infection, including the use of 67Ga-citrate scans
for AIDS-associated Pneumocystitis jirovecii infection.
However, there have been relatively few publications on the
nuclear imaging of coronavirus-associated SARS, and very
few of the surfeit of recent PET/CT case reports on COVID-
19 placed their findings into this wider context of respiratory
infections. Indeed, a PubMed search for the terms “PET/CT”
and “viral pneumonia” reveals only nine publications prior to
2019 (only two of which were truly reports of viral pneumo-
nias). In contrast, the same search for the year 2020 yielded 72
hits. This is noteworthy, since at least three pandemics of
respiratory pathogens have occurred subsequent to the advent
of multimodal PET/CT imaging (SARS-CoV-1 2002–2006,
H1N1pdm09 “Swine Flu” 2009–2010, and MERS-CoV
2012), not to mention the annual influenza season, which
frequently leads to excess winter mortality and places signif-
icant strain upon health systems. While there are significant
differences between COVID-19 and previous outbreaks, not
least in its magnitude, this dearth of data prior to the current
pandemic may nevertheless suggest that there had hitherto
been limited clinical requirement for additional [18F]-FDG-
PET/CT imaging in the management of individuals with viral
pneumonias. Alternately, this phenomenon may indicate what
has been termed a “covidisation” of research in 2020 [79].
Indeed, the preponderance of available studies is limited to
Fig. 5 A 48-year-old female was hospitalized with fever, cough, and
fatigue with a high index of clinical suspicion for COVID-19. [18F]-
FDG PET/CT revealed high levels of uptake in the lower lobe of the right
lung (a), the middle lobe (b), and in the left lower lobe (c) with patchy
opacities. High uptake was also observed in mediastinal lymph-node
stations 2R (d), 4R (e), and in the right hilum (f), as shown by the yellow
arrows
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case series or non-controlled observational data, and few stud-
ies have confirmed PET findings by laboratory testing or have
included negative or positive controls. There is therefore a
lack of data regarding the true sensitivity and specificity of
[18F]-FDG-PET/CT for COVID-19, which calls for cautious
interpretation of any suggestive findings. It is in this context
that we provide a critical overview of the currently available
data.
PET findings in viral pneumonia
The SARS-CoV-1 pandemic (2002–2004) was associated
with a considerably higher individual morbidity and mortality
in the acute phase than has been observed in 2020with SARS-
CoV-2. For this earlier outbreak, occurring only shortly after
the advent of dual modality PET/CT in clinical routine, only
sparse data using conventional imaging modalities are avail-
able. The few reports describe similar changes to those now
seen SARS-CoV-2, being indistinguishable from findings in
other viral pneumonias [80, 81]. There is a single case study
with [18F]-FDG PET/CT for the 2012–2015 Middle East re-
spiratory syndrome (MERS-CoV) pandemic. Similar to find-
ings with SARS-CoV-2, there was increased metabolic activ-
ity associated with the ground-glass opacities in the lung [82].
The spatio-temporal pattern of [18F]-FDG uptake in ferrets
with H1N1pdm09 virus reported by Jonsson et al. showed a
correlation between lesion standardized uptake value (SUV)
and bronchiolitis-related pathologic scoring, thus suggesting a
relationship between viral pathophysiology and PET findings,
albeit in an animal model [83]. In contrast, when assessing the
suitability of [18F]-FDG PET/CT for the characterization of
HIV-related bronchiectasis in children, Masekela et al. found
no correlation between PET findings and disease activity [84].
[18F]-FDG PET/CT has been investigated previously as a
means of therapy monitoring in respiratory infections and as
a diagnostic tool in cases of cryptogenic infection, such as
nosocomial or ventilator-associated pneumonia, although
these data are of a preliminary nature [85]. Therefore, there
is not yet any firm basis for interpreting the flurry of COVID-
19-related [18F]-FDG PET/CT data.
Epidemiology of PET findings
A variety of experiences with [18F]-FDG PET/CT from
around the world have been published, ranging from various
coincidental COVID-19-related findings [86], to rare cases of
positive results (23/1079 [87]), to significant findings in
clinics at pandemic hotspots. The frequency of findings, when
analyzed statistically and compared to epidemiological data,
may provide insights into the underlying dynamics of the pan-
demic [86, 88]. In Brescia, Italy, a case series of 65 [18F]-FDG
PET scans over an 8-day period in March 2020 showed six
scans with findings suggestive for COVID-19 (9.2%),
although, in accordance with the local guidelines, confirmato-
ry laboratory testing was not done in all patients [89]. That
same study reported a low incidence of findings suspicious of
viral pneumonia in a similar 8-day period in March 2019 (n =
2/80, 2.5%). Likewise, in a 3-day period in March 2020 in
Bergamo, Italy, 5/13 suspicious scans were identified, al-
though again, interpretation of these findings is confounded
by the lack of laboratory testing for all individuals and by the
blind antibiotic therapy then initiated for presumed bacterial
pneumonia in accordance with local guidelines [90]. Similar
results were reported for southern Italy by Maurea et al., ob-
serving significantly more findings suspicious for COVID-19
between Feb and April 2020 compared to 2019 [91]. Maurea
et al. reported their data using a standardized reporting system
(CO-RADS) in the interpretation of their scans [92], whereas
Pallardy et al. reported data from Nantes, France, using a
French classification system, which showed a small increase
in incidental findings (2.2% 2019 vs. 3.8% 2020) [93].
Notably, the presented cases included areas of minimal lung
involvement and were thus of questionable clinical impact. It
is unknown if such patients were in fact COVID-19 positive
and, if so, whether they were still infectious at the time of
scanning. In contrast to these data, Halsey et al. reported a
series of scans (n = 160) conducted in 2020 at an academic
center in London, UK; these scans were analyzed for inciden-
tal findings relative to a date-matched control group (n = 205)
from 2019. Although a high number (16.3%) of their 2020
patients had incidental findings, there was no significant dif-
ference in frequency compared to the 2019 control group. This
does suggest that such a high rate of incidental findings can be
common even in “normal times,” although the merits of
choosing 2019 scans as a control-group are perhaps question-
able; early indications suggested that the 2019 influenza sea-
son was then already (prior to COVID-19) on track to be one
of the worst in recent decades (https://www.cdc.gov/flu/about/
burden/preliminary-in-season-estimates.htm.). The winter of
2019 was therefore not a “normal” baseline for comparison.
In common to all these studies was the lack of laboratory
testing to confirm or refute COVID-19 diagnosis, and the
exclusion of symptomatic individuals. Examination protocols
(free-breathing vs. deep inspiratory breath hold acquisition
and reconstruction parameters) were not standardized, and
are thus likely to have had a considerable influence on the
results. Interpretation criteria varied between studies or relied
on the readers’ own interpretation of what constitutes a suspi-
cious finding. Levels of sub-speciality experience in the
reporting of thoracic imaging may also differ between centers.
There is considerable overlap between COVID-19-related ra-
diological findings and other causes of acute lung injury or
organizing pneumonia. Such suspicious findings, which these
studies report to be consistent with COVID-19, may be better
described under the more inclusive differential diagnosis of
“viral pneumonia,” which is in-keeping with the Radiological
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Society of North America consensus statement [94]. Reports
regarding the frequency of non-specific PET/CT findings
should therefore be interpreted with a high degree of caution.
Pathophysiological insights
Molecular imaging may provide insights into the underlying
pathophysiological characteristics of COVID-19, which, at
the time of writing (12 months into the pandemic), remain
poorly understood. Nassodi et al. call for the nuclear medicine
community to “look beyond the obvious,” referring to inci-
dental findings in [18F]-FDG PET [95]. Two case reports are
available for COVID-19-related findings in [68Ga]-PSMA-11
PET/CT (with non PSMA-avid classical ground class opaci-
ties in the CT) [96] and in [18F]-fluorocholine PET/CT for
recurrent prostate cancer (with fluorocholine-avid disease
and lymphadenopathy present) [97]. We find no other reports
of incidental COVID-19 findings with other PET tracers.
[18F]-FDG-PET/CT is a well-established modality for the im-
aging of inflammation [98]. Although [18F]-FDG-PET/CT re-
ports of Kawasaki-like vasculitis have been prominent in the
literature [99], no case reports are available of children with
COVID-19 undergoing nuclear medicine imaging with [18F]-
FDG PET. Coagulopathy is a notable extrapulmonary feature
in patients suffering from severe COVID-19 [100]. Although
the molecular imaging of the coagulation system is at a pre-
liminary stage, novel and promising techniques such as the
radiolabelled derivative of factor VII, 18F-FVIIai [101], hold
some promise as tools for future research.
Lung scintigraphy
Dysfunction of multiple organ systems has recently been de-
scribed in patients suffering from COVID-19 pneumonia
[102, 103]. Various publications report coagulopathy as an
accompanying manifestation of infection with SARS-CoV-2
[104]. The administration of low-molecular-weight heparin
during the hospitalization of COVID-19 patients was associ-
ated with reduced mortality [105], suggesting an underappre-
ciated impact of coagulopathy. Therefore, not only CT-
angiography [106] but also ventilation/perfusion single pho-
ton emission tomography (V/Q-SPECT) may play important
roles in excluding pulmonary embolism in cases of COVID-
19 pneumonia, especially when there is contraindication for
contrast-enhanced CT, e.g., renal failure [107–109].
According to the algorithm of Zuckier et al., lung scintigraphy
should be performed only with perfusion component (Q) to
minimize the risk of COVID-19 transmission and thus protect
nuclear medicine employees [109]. On the other hand, other
publications recommend performing V/Q-SPECT in COVID-
19 patients to reduce the rate of false positive results, which
they consider less likely to occur with V/Q-SPECT than in Q-
SPECT with low-dose CT [110, 111]. The mentioned
publications emphasize the importance that staff should use
protective equipment such as N-95 masks during the ventila-
tion procedure of COVID-19 patients undergoing diagnostic
examination [109].
In recent case reports, V/Q-SPECT/CT has emerged as an
alternative method to CT-angiography to exclude pulmonary
embolism in cases where CT-angiography could not be per-
formed [107, 112, 113]. Some authors present various exam-
ples of case findings in V/Q-SPECT/CT, reporting about the
great usefulness of lung scintigraphy to detect pulmonary em-
bolus in patients with COVID-19. Others report on instances
of patients with COVID-19 pneumonia in whom the ventila-
tion SPECT showed a heterogeneous pattern with preserved
perfusion of the lung parenchyma, even in the presence of
ground glass infiltrates to combined CT [112, 114]. In other
cases, patients presented heterogenous perfusion patterns,
where perfusion defects correlated with CT infiltrates, as
shown in Fig. 6 [112, 115]. Nevertheless, co-registered native
CT was helpful in cases of perfusion defects to exclude pul-
monary embolism and to match perfusion heterogeneities of
the scintigraphy to pulmonary infiltrates, which are frequent
findings in lung CT-scans of patients with COVID-19 pneu-
monia [107, 108, 116]. Thus, the workup of patients with
COVID-19 pneumonia benefits from having CT co-
registered to the V/Q-SPECT and seems especially useful if
only the perfusion SPECT is performed, rather than perfusion
and ventilation SPECT.
Cardiovascular imaging findings
Cardiovascular imaging in the initial phase of illness
In the initial phase of a SARS-Cov2-infection, the severity
and prognosis of the disease depend on the degree of pulmo-
nary involvement and on the presence or absence of acute
myocardial damage and multiorgan dysfunction [117, 118].
Older patients [119], patients with diabetes [120, 121], and
those with arterial hypertension [122] have a higher risk for
a severe course of COVID-19. Additional risk factors include
preexisting cerebrovascular and cardiovascular disease [123,
124], irrespective of gender, arterial hypertension, or diabetes
[125]. Diagnostic procedures in the initial phase of the disease
need to focus on physical examination, anamnesis, and the
analysis of clinical history and laboratory biomarkers, where-
as imaging mainly becomes necessary for determining the
presence and severity of pulmonary and cardiac involvement
by chest radiography, pulmonary CT [19], and echocardiog-
raphy [126]. Other cardiac imaging modalities, such as coro-
nary-CT, nuclear imaging, and cardiac magnetic resonance
imaging, are more frequently used in the subacute, convales-
cent, and chronic phases of SARS-CoV2-infection [127].
Acute myocardial damage is present in 11–16% of
COVID-19 patients with a severe course of disease, as
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indicated by elevated cardiac high-sensitivity troponin T (hs-
TnT) levels in plasma [128, 129]. Certainly, disease-related
myocardial damage is associated with a reduced long-term
survival [124, 130] in patients with and without pre-existing
coronary artery disease (CAD) [131]. The assessment of acute
myocardial damage is based on the presence in plasma of
elevated cardiac biomarkers (i.e., troponin, creatine kinase),
abnormal heart failure biomarkers (i.e., B-type natriuretic pep-
tides (BNP), NT-proBNP), and abnormal 12-lead electrocar-
diogram (ECG) suggestive of ischemia or myocarditis. In case
of suspected acute coronary syndrome, patients should under-
go immediate invasive coronary angiography [127]. If the
patient shows signs of left and/or right ventricular dysfunc-
tion, hemodynamic instability, or suspected pericardial effu-
sion, transthoracic echocardiography is the first-line imaging
modality [126].
For safety reasons, most centers have segregated their imag-
ing wards into separate sections for COVID-positive and non-
COVID-19 patients [13, 132]. Transthoracic echocardiography
procedures should be kept as brief as possible, to minimize the
exposure of healthcare personal to the pathogen. This procedure
includes a focused assessment of right and left ventricular global
systolic function and regionalities, as well as analysis of valvular
dysfunction and pericardial disease. Transesophageal echocardi-
ography puts the performing physician at risk of contamination
due to the aerosol generation that often occurs during intubation
of the probe [133], and the necessity of this procedure should
thus be carefully considered [134]. Cardiac CT, including an
arterial and venous phase scan, may present a safer alternative
in SARS-CoV2 patients to exclude non-invasively left atrial ap-
pendage thrombus due to atrial fibrillation before making a de-
cision to undertake converting or ablation procedures [135].
Fig. 6 Perfusion SPECT/CT im-
ages of a heterogenous perfusion
pattern in a case of COVID-19
pneumonia. Shown are the hybrid
images (a/b), the perfusion
SPECT (c/d), and the non-
contrast enhanced CT images (e/
f)
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Cardiovascular imaging in the subacute and convalescent
phase
The pathologic mechanisms by which SARS-CoV-2 can
cause myocardial injury remain elusive. Possible causal fac-
tors include myocardial injury resulting from direct damage to
the cardiomyocytes by the virus, systemic inflammatory re-
sponses, immune-mediated response by interferon and cyto-
kines, inflammation of the endothelium (i.e., endotheliitis)
with subsequent endothelial dysfunction [136], and direct cor-
onary plaque destabilization or microthromboembolism, with
consequently reduced myocardial perfusion [137].
Endothelial dysfunction in COVID-19 occurs following
the entry of SARS-CoV-2 particles into endothelial cells via
docking to the ACE2 transporter/receptor [137]. This process
induces endothelial inflammatory processes that provoke
plaque instability, as well promoting a pro-thrombogenic state
[138], which can lead to acute coronary syndrome, or to sys-
temic and pulmonary embolisms [139]. ACE2, now also
known to be the SARS-CoV-2 functional receptor, are found
not only in the epithelia of the lung and small intestine but also
in arterial and venous endothelial cells and arterial smooth
muscle cells in all organs studied, including the brain [140].
In a Dutch university hospital, 31% of intensive care unit
(ICU) patients with proven COVID-19 pneumonia had arteri-
al or venous thromboembolic complications [141]. Increased
plasma D-Dimer levels and prothrombin time were associated
with greater disease severity and independently predicted a
poor prognosis [142], with an increased risk for fatal outcome
[143].
Pulmonary embolism occurred in 22–30% of patients with
severe clinical features and oxygenation levels <92% who
underwent contrast enhanced chest CT [106, 144, 145]. In a
French multicenter study, pulmonary CT angiography was
performed in 1240 of 2878 consecutive patients (43%) hospi-
talized for SARS-CoV-2 infection, among whom pulmonary
embolism was found in 103 cases (8.3% of those with angi-
ography and 3.6% of all COVID-19 patients) [146]. Beside
venous thromboembolism, some authors hypothesized that
direct pulmonary artery thrombosis may arise due to the se-
vere lung inflammation and the hypercoagulable state in pa-
tients [147]. Pulmonary CT angiography is the best imaging
modality to exclude non-invasively pulmonary embolism
[148], irrespective to the exact pathomechanism of venous
thromboembolism or direct pulmonary artery thrombosis.
Thromboembolic complications of COVID-19 in the sys-
temic arterial circulation system include thromboembolism to
the upper and lower extremities [149], bowel ischemia [150],
and stroke or myocardial infarction [151]. While invasive cor-
onary angiography is routinely performed in patients present-
ing with an acute coronary syndrome, coronary CT angiogra-
phy (CTA) presents an alternative non-invasive imaging mo-
dality to rule out significant coronary artery stenosis in
patients with a low to intermediate pretest probability for cor-
onary artery disease [152] (Fig. 7).
Coronary CTAmay be performed with retrospective ECG-
triggering or prospective ECT-gated one-step acquisition, if a
CT scanner with high-pitch mode or large detector coverage is
available [153, 154]. Dilatation of the coronary arteries with
nitroglycerine spray and heart rate control with a beta-blocker
improves the diagnostic accuracy of the procedure [155, 156].
CT coronary angiography may be combined with a thoracic
CT angiography as a one-stop shop to rule out pulmonary
parenchymal involvement, pulmonary embolism, and coro-
nary artery disease [157, 158].
In patients with elevated cardiac troponin levels and no
coronary artery disease, myocardial damage may be mediated
by factors such as systemic inflammatory processes, cytokine
storm, multi-organ-dysfunction, or direct myocardial infiltra-
tion of the virus [159, 160]. There are case reports of SARS-
CoV-2 patients presenting with myocarditis [161–164], myo-
cardial infarction with non-obstructive coronary arteries
(MINOCA), or stress-induced Takotsubo cardiomyopathy
[165]. In a recent publication on 388 MINOCA patients (not
related to SARS-CoV-2), cardiac MRI supported a final diag-
nosis in 74% of cases. The final diagnosis was assigned in
equal proportions (25%) to myocarditis, myocardial infarc-
tion, cardiomyopathy, and a normal cardiac MRI. Patients
with cardiomyopathy (of whom 43% had Takotsubo cardio-
myopathy) had a higher mortality than those with any other
diagnosis, especially when the cardiomyopathywas combined
with ST-elevation on ECG [166]. Whether such associations
shall hold true as well for SARS-CoV2 patients warrants in-
vestigation. According to a position statement by the Society
of Cardiovascular Magnetic Resonance (SCMR), cardiac
MRI in COVID-19 patients should be focused on ventricular
morphology and function, as well as myocardial tissue char-
acterization [167, 168].
Cardiovascular imaging in the chronic phase
We know little about the chronic phase of SARS-CoV2 infec-
tion and the degree to which late cardiovascular consequences
are to be expected. In patients who recovered from a SARS-
CoV-2-infection with pulmonary involvement, right ventricu-
lar dysfunction and possible secondary tricuspid regurgitation
sometimes occurs due to pulmonary fibrosis with subsequent
pulmonary-artery hypertension [169]. In addition to impaired
right-ventricular function, some patients who had recovered
from SARS-CoV-2 showed ongoing myocardial inflamma-
tion, diffuse myocardial fibrosis, and Late-Gadolinium
Enhancement (LGE) [169] (Fig. 8). In one study with 100
patients who had recovered from a recent SARS-CoV-2 infec-
tion, cardiac MRI revealed cardiac involvement in 78 patients
(78%) and ongoing myocardial inflammation in 60 patients
(60%), examined 2–3 months after the positive SARS-CoV-2
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test [170]. Those patients showed elevated T1 and T2 map-
ping values, both ischemic and non-ischemic patterns of myo-
cardial LGE, as well as reduced left and right ventricular ejec-
tion fractions [170].
The link between myocardial inflammation and diffuse
myocardial fibrosis is well-known [171]. Diffuse myocardial
fibrosis may lead to left ventricular dysfunction and heart
failure [172]. Ongoing myocardial injury, pericardial inflam-
mation, microvascular ischemia, and fibrosis related to SARS-
CoV-2 infection are associated with ventricular tachycardia
[160, 173] and atrial fibrillation (AF) [174]. In a similar man-
ner, inflammatory processes provoked by SARS-CoV2 may
Fig. 7 The heart of a 64-year-old
female patient who had survived a
SARS-CoV-2 infection 4 months
previously. Now suffering from
dyspnea and chest pain. cvRF,
dyslipidemia. Results: CaSc 0, no
stenosis
Fig. 8 A49-year-oldmale patient. New onset of dyspnea NYHA III since
a SARS-CoV-2 infection 5 months ago. Cardiac MRI at 3T showing a
dilated, eccentrically hypertrophied left ventricle (LV-EDV 151 ml/m2,
LVmass 127 g/m2). Left ventricular (LV) ejection fraction (LV-EF 37%),
LV peak circumferential (−12%), radial (18%), and longitudinal strain
(−14%) were globally reduced, while the lowest regional peak
circumferential strain was found in the LV septum (−6%, asterisk, a).
Mid-ventricular Late-Gadolinium-Enhancement (LGE, b, c) was present
in the LV septum, with normal T2 relaxation time (40 ms, d) in T2
mapping, but prolonged T1 relaxation time (1330 ms, e, f), consistent
with myocardial fibrosis (white arrows)
Eur J Nucl Med Mol Imaging
induce long-term vascular damage and accelerate the forma-
tion of atherosclerotic plaques in the coronary arteries and the
aorta, which is a theme yet to be investigated in long-term
follow-up studies [175].
Molecular cardiovascular imaging
Nuclear medical imaging methods such as myocardial perfu-
sion imaging/MPI do not yet play a relevant diagnostic role in
the context of COVID-19, as dictated by logistical and social
factors. According to a joint statement of the American
Society of Nuclear Cardiology (ASNC) and the Society of
Nuclear Medicine and Molecular Imaging (SNMMI) from
March 2020, all non-urgent diagnostic imaging studies, in-
cluding nuclear cardiology procedures, should be postponed
in order to minimize the spread of COVID-19 and to conserve
hospital resources in the face of the pandemic [176, 177].
The effect of implementing these measures was evident in
an Italian study showing a significant reduction in the number
of stress SPECT-MPI studies during the COVID-19 pandemic
compared with the corresponding months of the previous 3
years, whereas there was no difference in the prevalence of
abnormal SPECT-MPI studies between the study periods
[178]. The authors concluded abnormal imaging tests are like-
ly missing for many heart patients during the pandemic.
Furthermore, an international survey extending from April
16 to May 3 2020, which included responses from 72 coun-
tries, reported a 66% decline in the number of myocardial
studies [179]. This result was recapitulated in other studies
showing decreasing case numbers [180–182].
To facilitate an assessment of the urgency and justification
for undertaking SPECT-MPI studies, the ASNC and SNMMI
have given guidance using a three-level system for prioritizing
nuclear cardiac examinations for different indications [176].
Especially for patients with confirmed or suspected COVID-
19, referring physicians are advised to discuss the matter with
a nuclear cardiologist or physician and to rationalize the ab-
solute urgency for ordering an MPI or other procedures [183].
If other simpler imaging modalities are available for resolving
clinical questions, they should be used preferentially. Thus,
nuclear cardiology imaging in COVID-19 patients should be
restricted to indications with no adequate alternative imaging
modality, and having direct clinical consequence, for instance
the urgent use of FDG-PET/CT for suspected infective endo-
carditis in the setting of prosthetic valves or intracardiac de-
vice infection [158, 176].
If it proves necessary to conduct an FDG-PET/CT exami-
nation, the ASNC/SNMMI guidelines include special recom-
mendations for measures at nuclear cardiology facilities, in
addition to the standard procedures like masking, social dis-
tancing, and hand hygiene [176]. These included selecting a
protocol with the shortest possible scanning duration and least
patient exposure time to staff, as well as the preferred use of
first/stress only in single-day imaging protocols [176, 177].
Furthermore, manual blood pressure measurements should
be avoided [133, 176, 177].
As the SARS-CoV-2 virus spreads via aerosol droplets,
procedures that might involve patient coughing or otherwise
releasing aerosols are high risk [183]. Therefore, exercise
stress testing for MPI should be avoided and pharmacological
stress, e.g., with vasodilators, should be preferred [176, 183,
184]. Since the A2A adenosine receptor agonist vasodilator
Regadenoson only requires a 10-s infusion calling for close
proximity of staff to the patient, it is the preferred stress agent,
if not medically contraindicated [176]. Otherwise, it could be
possible to use extra-long tubing to maximize the distance
between staff and patient when administering adenosine or
dipyridamole [176]. If exercise stress testing is deemed nec-
essary in settings with moderate to high prevalence of active
COVID-19, virus testing of the patient is recommended prior
to the examination, and exercise protocols should be kept as
brief as possible [133]. Moreover, if [82Rb] or [13N]-ammonia
myocardial perfusion PET is available, it is preferable to myo-
cardial perfusion scintigraphy due to its better efficiency, such
that the complete rest-stress study acquisition last only 30 to
45 min [133, 177].
However, there are also circumstances and indications
when nuclear medical procedures entail a lower risk of
SARS-CoV-2 transmission compared to other diagnostic
methods. For example, in febrile patients with bacteremia
and suspicion of endocarditis, clinicians should consider
FDG-PET/CT as a safer alternative to transesophageal echo-
cardiography, which is apt to provoke considerable aerosol
and droplet release [176].
Overall, pathologies associated with COVID-19 or sus-
picious for COVID-19 have generally been incidental
findings on cardiological nuclear imaging, especially in
SPECT/CT-MPI. In one case report, a man with a history
of hypertension and dyspnea on exertion was referred for
preoperative risk stratification prior to renal surgery [185].
After exercise stress testing, MPI with [99mTc]-Sestamibi
showed stress-induced ischemia in the apical septal seg-
ment. Furthermore, there were multifocal ground glass
opacities with pathologically increased uptake of
[99mTc]-Sestamibi in both lungs, which were interpreted
as typical features of COVID-19 lung involvement.
However, there was no confirmation of the suspected in-
fection by testing for SARS-CoV-2. Nevertheless, the pa-
tient was placed under quarantine and monitored. In an-
other case report, myocardial perfusion scintigraphy with
99mTc-Sestamibi was performed on a D-SPECT® camera,
which showed normal gated stress images but also high
signal in both lungs [186]. An additional CT in the patient
showed ground-glass opacity and a crazy-paving pattern
suggestive of COVID-19, with subsequent confirmation
by RT-PCR analysis of a nasal swab.
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In a study from the UK, 160 [18F]-FDG-PET/CT scans in
asymptomatic patients and those with symptoms not primarily
suggestive of COVID-19, but dating from the period of the
lockdown, were reviewed retrospectively for incidental find-
ings in the lungs and in extrapulmonary sites [187]. Among
these 160 cases, one showed focal right ventricular uptake,
one a patchy right ventricular uptake, and another had one
diffuse right ventricular uptake, suggesting perhaps 2% inci-
dental positivity. However, there was no systematic testing for
SARS-CoV-2 for these patients. In another study, the aim was
to assess by [18F]-FDG-PET/CT the inflammatory status at the
presumed peak of the inflammatory phase in non-critically ill
patients (n = 13) admitted for COVID-19 [188]. Patients en-
rolled prospectively underwent an [18F]-FDG PET/CT exam-
ination from day 6 to day 14 after onset of symptoms. Only
one of these patients had significant physiological myocardial
FDG uptake, even though there had been no intervention to
suppress physiologic myocardial glucose metabolism prior to
scanning, such that one might normally have expected sub-
stantial myocardial tracer uptake in most individuals. The au-
thors suggested that the myocardial metabolic pathway may
disfavor glycolysis during COVID-19 infection, perhaps due
to a loss of sympathetic tone that would otherwise promote
myocardial FDG uptake [189], a conjecture that might be
tested by examination of cardiac variability or perhaps by
[123I]-MIBG scintigraphy.
In another case report, a 57-year-old COVID-19-positive
man with no history of cardiovascular disease had ground-
glass opacities on CT detected on the day of hospital admis-
sion [190]. Due to his poor response to symptomatic treat-
ment, worsening symptoms of chest tightness, and palpita-
tions, the patient underwent [18F]-FDG-PET/CT and [18F]-
FDG-PET/MRI examinations. The [18F]-FDG-PET/CT
showed focal ground-glass opacities in both lungs without
hypermetabolism, suggestive of the absorption phase of
SARS-CoV-2 infection, and revealed normal-sized but hyper-
metabolic and probably inflammatory mediastinal lymph
nodes. A subsequent [18F]-FDG-PET/MRI did not show any
pathological cardiac findings, but did reveal a diffuse increase
in hepatic [18F]-FDG-uptake consistent with a systemic in-
flammatory response. Due to the lack of cardiovascular in-
volvement, the authors suggested that their case study did
not indicate a clear association between the tissue distribution
of ACE2 and organ damage [190]. As ACE2, which enables
the entry of SARS-CoV-2 into cells, also has high expression
in the heart, cardiac tissue is likely to be vulnerable to the
infection. In a case report of a male cardiology patient from
a north Italian COVID-19 high-risk region, [18F]-FDG-PET/
CT was used to check for superficial and deep lead tract in-
fection of his left ventricular assist device. Results showed an
inflammatory pattern at the second and third level (superficial
tract) of driveline tunneling suggestive of a locally active in-
fection and potential evolution into a subcutaneous abdominal
fistula [191]. Furthermore, there were incidental findings of
multilobular subpleural ground-glass opacities in the lung
with increased [18F]-FDG-uptake that were suggestive of
COVID-19. A subsequent RT-PCR test was negative, but a
second test 8 days later was positive for SARS-CoV-2.
In conclusion, nuclear cardiology imaging is not presently
playing a major role in the evaluation of cardiac involvement
in COVID-19. Nevertheless, practitioners should be alert to
the possibility of incidental pulmonary findings, especially
since patients with cardiologic illnesses are a high-risk group
in the event of COVID-19 infections. Furthermore, guidelines
call for adaptation of imaging procedures to minimize the risk
of transmission between patients and medical staff.
Neurological imaging findings
Conventional imaging
Central nervous system (CNS) involvement is a known com-
plication of viruses with neurotropic characteristics. There are
also reports of neurological symptoms in patients with SARS-
CoV-2 infection, indicative of the neurotropic nature of the
virus [192]. Adverse neurological symptoms have occurred in
the form of anosmia, hyposmia, dysgeusia, headache, nausea,
vomiting, agitation, delirium, and impaired consciousness
[192–196]. Coronaviruses (CoVs) are generally neurotropic
[197], and both SARS-CoV and MERS-CoV have occasion-
ally caused clinically relevant CNS infections [198–202],
while SARS-CoV particles have been detected in neurons of
the human brain [203]. It is also likely that SARS-CoV-2 may
gain access to the CNS where it can induce neuronal injury.
Three hypotheses of SARS-CoV-2 entry into the CNS have
been discussed: (a) intranasal inoculation with spread via ol-
factory nerves and olfactory bulb to the brainstem; (b)
transsynaptic spread from neuron to neuron via endocytosis/
exocytosis, and (c) hematogenous spread via infected mono-
cytes and passing the blood-brain barrier [204].
Pathophysiology of CNS manifestations from COVID-19 in-
cludes three mechanisms: (a) direct viral entry into the brain,
(b) adverse immune response, and (c) respiratory stress [205].
Recent experimental evidence demonstrates that a human
CoV strain, HCoV OC43, can travel from the nasal cavity to
the olfactory bulb, and then spread to the piriform cortex and
ultimately to the brainstem, via both passive diffusion and
axonal transport [206, 207]. Animal studies have shown that
the viral infiltration started in the olfactory bulb and progres-
sively invaded subcortical and cortical regions. Anosmia was
reported in 5.1% and ageusia in 5.6% of 214 COVID-19 cases
in the first study from Wuhan [208]. A large multicenter
European study reported olfactory impairment in 85.6% and
gustatory dysfunction in 88% of 417 COVID-19 patients
[209]. However, a recent study from Spain documented anos-
mia in only 4.9% and ageusia in 6.2% of 841 COVID-19
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patients [210]. In an early post-mortemMRI study in COVID-
19 non-survivors, olfactory bulb asymmetry and atrophy was
detected in 4 of 19 (21%) subjects [211]. MRI signal alter-
ations of the olfactory bulb (Fig. 9) along with bilateral atro-
phy and signal increase in the gyrus rectus were reported in a
case study with examination at 4 days after the onset of anos-
mia [212].
In the first small series from the USA, five cases of large-
vessel stroke in patients with severe acute respiratory syn-
drome were reported [213]. A retrospective study from
Wuhan/China showed that the incidence of stroke among hos-
pitalized patients with Covid-19 was approximately 2.8%
[214]. The percentage of reported COVID-19-related strokes
varies considerably in different patient series. In a French
series of 58 patients, stroke was documented in 5% (3 of 58)
[195], but only 2% (50 of 235) of patients had stroke in a
Turkish study [215]. In a larger Spanish study, 50 of 841 of
COVID-19 cases (1.3%) had cerebral large-vessel occlusions
[210]. The highest incidence of COVID-19-related strokes
was reported in an Italian study (34 of 119, 28.6%) [216]. In
a retrospective cohort study of 3218 hospitalized COVID-19
patients in New York, 454 (14.1%) underwent neuroimaging,
with stroke being the most common finding (92.5%) [217].
Large infarcts were detected in 44.5% of the cases, whereas
lacunar infarcts were diagnosed in 24% [217]. It seems that
strokes in SARS-Cov-2 infection may be the result of two
different mechanisms, namely transient hypercoagulability
and/or systemic vasculitis/endotheliitis [192, 204]. In recently
published study from the UK, in 6 of 8 patients with stroke, D-
dimer was significantly raised indicating hypercoagulability;
four of the stroke patients had thrombus in intra- or extracra-
nial vessels, and four had a pulmonary embolism [192].
Another scantly explored neurological manifestation of
COVID-19 is meningitis/encephalitis. The first report on
SARS-CoV-2-associated meningitis/encephalitis from Japan
reported high signal intensity in the mesial temporal lobe
[218]. Interestingly, RT-PCRwas negative in the nasopharyn-
geal swab of that patient but was positive in the cerebrospinal
fluid (CSF). A large French observational retrospective study
reported unilateral FLAIR and/or diffusion abnormalities in
the MRI in 43% of cases [195].
Once entering the CNS, the virus can induce a dysregulated
host immune response known as “cytokine storm” [219]. The
cytokine storm and the direct cytopathic damage by the virus
particles may lead to neurological diseases, such as encepha-
litis, acute flaccid paralysis, or acute necrotizing encephalop-
athy (ANE) in susceptible individuals. In one case report from
the USA, MRI showed hemorrhagic rim-enhancing lesions
within the bilateral thalami, medial temporal lobes, and
subinsular regions consistent with ANE [220], which is a
well-known complication of influenza and other viral agents
[221–223].
There are reports of acute disseminated encephalomyelitis
(ADEM), cytotoxic lesions of the corpus callosum (CLOCC),
transient encephalopathy, and leptomeningeal enhancement in
association with COVID-19 [192, 195, 215, 224]. Clinically
transient encephalopathy manifested as delirium and psycho-
sis [192]. The negative RT-PCR in the CSF of such cases
suggests an underlying mechanism from secondary processes
rather than direct viral infection of the CNS. Miller-Fisher
syndrome and Guillain-Barré syndrome have been reported
to precede COVID-19 infections, suggesting a para- or post-
viral process.Haemophilus influenzae, Campylobacter jejuni,
ZIKA virus, and cytomegalovirus are the most common path-
ogens involved. Bickerstaff’s encephalitis overlapping with
Guillain-Barré syndrome, intensive care unit-acquired weak-
ness, or other toxic or infectious neuropathies have been re-
ported during or after Middle East respiratory syndrome
(MERS-CoV) treatment. Two patients infected with SARS-
CoV-2 presented with Miller-Fisher syndrome and polyneuri-
tis cranialis [225]. Serum GD1b-IgG antibodies were positive
in one of the reported patients, supporting the hypothesis of
immune-mediated injury rather than direct viral neurotropism.
Molecular neuroimaging
Although respiratory diseases are clinically prominent in the
context of infection with SARS-CoV-2, there are increasing
reports of neurological manifestations [226]. Despite neuro-
logical imaging usually being an MRI/CT domain in patients
with SARS-CoV-2 infections [227], there are cases where
nuclear medical procedures (especially [18F]-FDG-PET/CT)
have been used. For example, brain MRI, CSF testing, and
[18F]-FDG-PET/CT were performed in the case of a 72-year-
old man with a positive oropharyngeal swab test for SARS-
Fig. 9 Coronal T2-WI MR image in a patient after COVID-19 and
hyposmia demonstrates bilateral atrophy of the olfactory bulb (yellow
circle)
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CoV-2 who presented with a subacute cerebellar syndrome
and myoclonus following general infectious symptoms.
Brain MRI and CSF testing did not show any pathological
findings, whereas brain [18F]-FDG-PET/CT showed diffuse
cortical hypometabolism along with hypermetabolism in the
putamen and cerebellum, consistent with encephalitis, and
especially cerebellitis. Furthermore, this patient had high se-
rum and CSF titers of IgG autoantibodies against the nuclei of
Purkinje cells as well as against striatal and hippocampal neu-
rons. The case revealed a possible relationship between
SARS-CoV-2 infection and autoimmune encephalitis, where
[18F]-FDG-PET/CT had diagnostic advantages over brain
MRI [228].
Another recent publication included four patients with
encephalopathy related to COVID-19 (confirmed by a pos-
itive RT-PCR assay from a nasopharyngeal swab) [229].
The patients, who were aged at least 60 years, showed vari-
ous degrees of cognitive impairment mainly suggestive of
frontal lobe disorders, which were associated in part with
anosmia (n = 2), cerebellar syndrome (n = 2), myoclonus
(n = 1), psychiatric manifestations (n = 1), and status epilep-
ticus (n = 1). None of the four patients showed signs of en-
cephalitis on MRI and CSF analyses, including RT-PCR for
SARS-CoV-2, did not show any significant abnormalities.
On [18F]-FDG-PET/CT, all four patients showed a common
pattern of hypometabolism in the prefrontal or orbito-frontal
cortices and hypermetabolism in the cerebellar vermis, de-
spite their distinctly different neurological presentations.
The authors supposed that the central focal neurological
signs or seizures, the absence of meningitis and of SARS-
CoV-2 in the CSF, and the [18F]-FDG-PET/CT findings
were suggestive of a parainfectious cytokine-storm with
post-infectious autoantibody- or cell-mediated immune
mechanisms rather than a direct viral neuroinvasion. They
further argued that the elevatedCSF level of interleukin-6 (in
both patients examined for this), as well as the clinical im-
provement after immunotherapy, was indicative of a tran-
sient immune process [229]. Nevertheless, in the absence
of a control group, the possibility of a spontaneous amelio-
ration cannot be excluded.
Neurological complications can arise from other respirato-
ry viruses, especially seasonal and pandemic influenza [206].
Two prominent examples are anosmia and ageusia, which are
very common neurologic symptoms of COVID-19 appearing
either in isolation or together with other features [226, 230,
231]. These sensory deficits are often an initial manifestation
of the disease [232]. Although such symptoms can occur in
any respiratory infection, simply due to rhinitis, their isolated
occurrence prior to COVID-19 onset strongly suggests an
involvement of the olfactory nerve [226]. Furthermore, these
sensory symptoms were noted more frequently among
COVID-19 patients than for a historical influenza patient co-
hort [232].
An [18F]-FDG-PET/CT examination was performed in a
27-year-old right-handed woman, who had been earlier diag-
nosed with COVID-19 by RT-PCR and suffered from isolated
anosmia persisting for 6 weeks [233]. The scan showed path-
ological hypometabolism of the left orbitofrontal cortex [233,
234], a region which receives projections from the primary
olfactory cortex [235, 236]. Hyposmia and anosmia due to
CNS damage of other etiologies have previously been widely
investigated by molecular imaging, especially in the context
of Parkinson’s disease [237–239], where anosmia is an early
presenting symptom.
Iatrogenic neurological complications may occur in the
context of therapy for pre-existing conditions. In a recent case,
leukoencephalopathy emerged after long-term administration
of Tocilizumab in a COVID-19 patient with rheumatoid ar-
thritis. The patient showed leukencephalopathy on brain MRI,
with a lactic acid peak on magnetic resonance spectroscopy in
the left temporal lobe, decreased cerebral perfusion in SPECT,
and hypometabolism of the left frontal lobe in [18F]-FDG-
PET/CT [240] . Figure 10 shows an example of
leukoencephalopathy.
Tocilizumab is a monoclonal antibody directed against the
interleukin-6 receptor, which has also proposed as a treatment
to mitigate the cytokine-storm syndrome sometimes associat-
ed with severe COVID-19 [241]. Indeed, Tocilizumab treat-
ment has apparently imparted reduced mortality of patients
with COVID-19 requiring intensive care unit support [241].
Nonetheless, the potential for adverse neurological effects of
Tocilizumab should be considered when treating COVID-19
patients.
Although molecular imaging currently plays a minor role
in neuroimaging of SARS-CoV2 infections, it might yet gain
importance in the diagnosis of autoimmune encephalitis once
the clinical use of [18F]-FDG-PET/CT for this indication be-
comes more widely appreciated [239, 242]. This procedure
could prove very helpful in the diagnostic workup, as there
are known cases of likely autoimmune (steroid responsive)
but seronegative encephalitis and conversely of seropositive
autoimmune encephalitis in the context of SARS-CoV-2 in-
fection, with absence of any alterations onMRI [228, 243]. As
far as may be judged from the few available case reports,
hypometabolism on [18F]-FDG-PET/CT could serve as a ce-
rebral quantitative biomarker of neuronal involvement [244,
245] and should therefore be considered especially in
COVID-19 patients presenting with anosmia or any acute
central nervous system impairment [229]. However, larger
viral and post-viral cohort studies shall be required to confirm
any relationship between pathological findings on [18F]-FDG-
PET/CT and distinct neurological disorders such as persistent
cognitive or emotional disturbances as well as pain syn-
dromes. Furthermore, longitudinal [18F]-FDG-PET/CT stud-
ies could prove to be useful to determine whether pathological
PET findings are attributable to a transient functional
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inactivation or rather to irreversible brain damage [229]. We
furthermore note the precedent set by [18F]-FDG-PET find-
ings in patients with chronic fatigue syndrome [246], which is
arguably a post-viral condition. As such, [18F]-FDG-PETmay
assume a growing importance in the years to follow the pres-
ent pandemic.
Additional organ manifestations of COVID-19
Symptomatic patients suffering of COVID-19 typically pres-
ent with symptoms caused by acute lung injury such as fever,
cough, and dyspnea. However, rising testing capacities and
case numbers have led to the emerging understanding of
COVID-19 as a systemic disease, affecting not only the pul-
monary, cardiovascular, or neurological systems, as reviewed
above, but also extending to other systems such as the renal,
gastrointestinal (GI), or the hepatobiliary system. Against this
background, there is an increasing awareness of these mani-
festations and their associated imaging findings.
The pathophysiological mechanism of abdominal organ
damage by COVID-19 derives from the type II pneumocytes
of the lung. As in the case of pulmonary and vascular infec-
tions, the virus probably gains access to visceral organs via
their surface expression of ACE2. This docking site has broad
expression in the human viscera, thus enabling direct or indi-
rect tissue damage of the liver, biliary ducts, pancreas, spleen,
intestine, or kidneys [118, 247–253]. A hepatocellular injury
pattern is assuming an increasing clinical importance, now
evident in 14–53% of critically ill COVID-19 patients [122,
254–256]. It shall be important to follow-up patients receiving
investigational antiviral treatments such as remdesivir,
lopinavir, or tocilizumab, due to their potential for causing
drug-induced liver injuries [257]. The ultrasound findings of
hepatobiliary manifestations of COVID-19 reported in the lit-
erature include signs of biliary stasis such as gallbladder
sludge and distension, as well as ascites [258–260].
Occasionally, CT findings of acute cholecystitis or pancreati-
tis have been reported [260]. However, it seems very likely
that CT, MRI, or ultrasound examinations may prove to detect
features of hepatic steatosis in COVID-19 patients.
Gastrointestinal manifestations in COVID-19 patients are
also of great clinical importance, considering that bowel wall
abnormalities were a frequent finding upon admission to an
ICU [258]. The incidence of gastrointestinal involvement
ranges from 12 to 61% in the literature. Although being more
frequent among patients with longer duration of COVID-19
illness and ICU submission, gastrointestinal findings have not
yet been associated with increased mortality [248, 255, 258,
261–263]. Some studies describe a small percentage of pa-
tients in whom the gastrointestinal symptoms preceded the
pulmonary manifestations, or who presented only with symp-
toms such as nausea, vomiting, diarrhea, or abdominal pain
[167, 225, 248, 263].
The most commonly reported gastrointestinal imaging
finding is bowel wall thickening, which can include all parts
of the bowel [258–260]. In the COVID-19 cohort of Bhayana
et al., bowel wall thickening was associated with admission to
the ICU, and small bowel thickening was an exclusive finding
in ICU patients [258]. Others have reported various imaging
findings, including intestinal pneumatosis, pneumoperitone-
um, portal vein thrombosis, and portal venous gas, all of
which are associated with mesenteric ischemia [258–260]. A
possible explanation for these findings may be the high ex-
pression of ACE2 not only in enterocytes but also on the
vascular endothelium, making the visceral structures highly
susceptible towards infection by the virus. The occurrence of
Fig. 10 a, bA 44-year-old female
patient with COVID-19 and se-
vere ARDS. Axial FLAIR MR
images show bilateral, ill-defined
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microvascular small-bowel injury is suggested by the histo-
pathological presence of diffuse endothelial inflammation in
the submucosal vessels of the small intestine in COVID-19
patients [264]. Furthermore, the infection can give rise to a
systemic coagulopathy, especially in critically ill patients
[265], as described in the preceding sections. Occasional gas-
trointestinal findings include ascites, fluid-filled colon, colon-
ic ileus, and cases of ileocolic intussusception [102, 266–268].
In consideration of these possibly life-threatening complica-
tions and of the fact that COVID-19 patients with primary
gastrointestinal symptoms often experience delayed diagno-
sis, there is a need for vigilance about the need for imaging in
patients with these manifestations [248, 269].
Acute kidney injury (AKI) presenting with proteinuria and
hematuria is a severe possible complication of COVID-19,
which imparts high mortality [270–273]. In a study from the
USA, there was a 37% incidence of 37% of AKI among
COVID-19 patients, of whom one-third had diagnosis within
24 h after admission, and 14% even required dialysis [272].
Renal pathophysiology is probably multifactorial, but SARS-
CoV-2 may directly target renal cells via ACE2, as is support-
ed by certain histopathological findings [118, 253]. Another
possibility is that AKI is caused by cytokine-storm during the
infection, as can occur during infections with influenza and
other viruses [274]. Of course, other potential etiologies of
AKI in critical illness situations also remain relevant, among
which are organ volume depletion, interstitial nephritis,
ARDS, or rhabdomyolysis [275]. Renal imaging findings
are rarely reported in the COVID-19 literature, the most com-
mon being signs on MR of renal infarction, namely sharply
demarcated, possibly patchy hypoenhancing or non-
enhancing areas in the kidney [276–278]. In pathophysiolog-
ical terms, this kind of lesion is most probably attributable to
the global coagulopathy that can occur in COVID-19 [265,
279].
Although myalgia is a commonly reported symptom
among COVID-19 patients [280, 281], musculoskeletal man-
ifestations are most probably underdiagnosed, such that so far
only one imaging result is yet available in the literature, being
an MR study of acute myositis [282]. We emphasize that new
COVID-19 manifestations such as peripheral nerve disease or
neuromusculoskeletal disorders seem likely to emerge with
time, in keeping with the precedent set by SARS-CoV-1.
However, there are not yet reports of such findings in
SARS-CoV-2 patients [283, 284].
Another rare manifestation of COVID-19 is cutaneous le-
sions including maculopapular rash, vesicular lesions, and
livedoid/necrotic lesions, with the latter possibly being asso-
ciated with a more severe course of COVID-19 [285]. A
single-center observational study from Italy first reported that
dermatologic manifestations occurred in 20% of patients hos-
pitalized with COVID-19 [286]. There was no significant cor-
relation between severity of respiratory symptoms and
dermatologic manifestations, and there are not yet any specific
imaging findings of cutaneous manifestations reported in the
literature.
Artificial intelligence in the diagnosis of COVID
Recent advances in artificial intelligence (AI) and specifically
in deep learning (DL), along with the availability of large
datasets and powerful computational hardware based on
graphics processing units (GPUs), have led to substantial
changes in medical imaging. AI extends human powers of
the perception of information in data, and may surpass human
performance in some situations [287, 288]. AI based on the
analysis of thoracic images has already contributed to the fight
against the COVID-19 pandemic, particularly in assisting the
diagnosis, stratification, prognosis, and treatment of COVID-
19 patients [289–291]. AI-based systems for radiomic analy-
sis of chest X-ray (CXR) images are playing a prominent role
in the newly introduced approaches and are now finding ap-
plication for lung ultrasound (LUS) images.
AI-based analysis of CRX images mainly focuses on the
development of support systems for the rapid diagnosis and
differentiation of COVID-19 from other types of pneumonia.
Various DL-based approaches have been published [71,
292–294], but only a few of these approaches have been val-
idated against radiologists. There was an investigation of the
accuracy of a DL-based system on the two-class problem of
discriminating COVID-19 vs other pneumonias on CRX im-
ages [295]. The algorithm in that study was pretrained on
publicly available data and fine-tuned on data collected from
four local medical centers. The performance of the trained
system was then compared with consensus findings of three
board-certified radiologists, which showed that the DL system
had higher sensitivity but similar specificity as did the radiol-
ogists. A similar investigation using a larger dataset was pre-
sented in [296], where a DL-based system using an ensemble
of networks was compared against three experienced thoracic
radiologists. The results indicated that the system
outperformed the experienced radiologists. The two-class di-
agnosis of COVID-19 vs no COVID-19 on CRX was ad-
dressed in [297], where an ensemble of convolutional neural
networks was pretrained on publicly available data, fine-tuned
on data collected from local clinical sites, and then compared
with decisions by five experienced radiologists. The results
showed that the DL-system was about as accurate as the con-
sensus of the experienced thoracic radiologists. The three-
class problem of COVID-19 pneumonia vs other pneumonia
vs normal was addressed by [298], where the performance of a
dedicated DL-system was compared against six readers. The
system performance was comparable with that of six indepen-
dent readers. In a more recent study [299], the performance of
a newly introduced DL-based system trained on publicly
available datasets was compared against 11 radiologists for
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the three-way discriminatory diagnosis of COVID-19 pneu-
monia vs. other pneumonias or normal. The system detected
COVID-19 very accurately and outperformed radiologists at
various training levels, while it was able to separate COVID-
19 pneumonia from other types of pneumonia more accurately
thanwere the human readers. Finally, in [300], a DL algorithm
was introduced to calculate a measure of pulmonary disease
severity on confirmed COVID-19 CXRs, with very encourag-
ing results and in good agreement with follow-up CRXs.
Since the very beginning of the COVID-19 pandemic, several
studies have examined the AI-based analysis of lung CT images.
This was initially applied to the task of differentiatingCOVID-19
from other lung diseases [301, 302], and more recently to assess
its severity [303] and prognosis [304, 305]. The initial attempts
contained a limited number of cases without expert validation.
Nevertheless, the results clearly indicated that AI technology is
potentially valuable in the diagnosis of COVID-19 using CT
imaging. In a recent study [306], the performance of a DL-
based algorithm trained on publicly available CT images was
compared against two experienced radiologists. The results indi-
cated that the system was slightly superior to the radiologists. In
[307], a CT-based triage system was introduced that was able to
alert physicians when imaging features suggestive of COVID-19
pneumonia were detected. ADL system subsequently developed
using a large data set performed remarkably well on an external
validation set. Positive cases were identified by machine much
more rapidly than by a radiologist, including the time require to
draft and release the report. The affected lung areas identified by
DL were also in good agreement with the radiologist’s report.
Furthermore, the development and multicenter validation of the
decision support system using clinical and laboratory variables
along with radiological variables derived by CT images for se-
verity risk assessment during hospitalization was presented in
[308]. In that study, the results of the radiomic analysis were
compared to the performance achieved by the pneumonia sever-
ity index (PSI), a clinical assessment method, indicating that the
DL approach has the potential to be used for assessing the onset
of severe and critical illness among COVID-19 patients.
LUS image analysis was proposed in [309] to evaluate the
progression of COVID-19 pneumonia based on the severity of
lung involvement. In [310], the authors trained a DL-based sys-
tem onLUS collected at five clinical centers in Italy to predict the
disease severity score proposed in [309]. In addition, others used
a neural network to predict diagnostic outcomes [311]. The net-
work was trained on publicly available videos and images and
achieved promising results. None of these LUS systems has yet
been validated against trained experts.
Conclusion
Although there is a long history of nuclear imaging in infec-
tious diseases of the chest, there is no current indication for the
use of PET/CT in routine clinical diagnosis or management of
COVID-19. However, in this still poorly understood disease,
multi-modal imaging may shed light on the underlying path-
ophysiological processes involved. Furthermore, well-
established nuclear medicine research tools such as the
radiolabeling of immune or inflammatory cells for PET imag-
ing [312, 313] serve as an example of how molecular imaging
could assist in the development of innovative therapies.
We aimed in this comprehensive review article to provide
an overview of the current knowledge on COVID-19 and
imaging. It is apparent that SARS-CoV-2 infection is a sys-
temic disease that can affect multiple organ systems besides
the lungs. Radiological exams have played a pivotal role in the
detection and diagnosis as well as patient management since
the very beginning of the pandemic. The authors of this article
gathered evidence from all across the field of medical imaging
and summarized the state-of-knowledge on COVID-19 in late
2020 and early 2021. However, we acknowledge that knowl-
edge is lacking for many aspects of COVID-19, including the
imaging results for mid- and long-term effects, which is a
research topic for the coming years.
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